71 related articles for article (PubMed ID: 35077445)
21. IL-2Rα up-regulation is mediated by latent membrane protein 1 and promotes lymphomagenesis and chemotherapy resistance in natural killer/T-cell lymphoma.
Wang L; Bi XW; Zhu YJ; He YZ; Lai QY; Xia ZJ; Cai QQ
Cancer Commun (Lond); 2018 Oct; 38(1):62. PubMed ID: 30340635
[TBL] [Abstract][Full Text] [Related]
22. Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways.
Hideshima T; Ogiya D; Liu J; Harada T; Kurata K; Bae J; Massefski W; Anderson KC
Leukemia; 2021 Jan; 35(1):177-188. PubMed ID: 32238854
[TBL] [Abstract][Full Text] [Related]
23. Expression of T-cell receptor signalling pathway components in extranodal NK/T-cell lymphoma.
Miyata-Takata T; Chuang SS; Takata K; Toji T; Maeda Y; Sato Y; Yoshino T
Histopathology; 2018 Dec; 73(6):1030-1038. PubMed ID: 30102799
[TBL] [Abstract][Full Text] [Related]
24. Regulatory mechanisms in T cell receptor signalling.
Gaud G; Lesourne R; Love PE
Nat Rev Immunol; 2018 Aug; 18(8):485-497. PubMed ID: 29789755
[TBL] [Abstract][Full Text] [Related]
25. Human NK Cells Downregulate Zap70 and Syk in Response to Prolonged Activation or DNA Damage.
Pugh JL; Nemat-Gorgani N; Norman PJ; Guethlein LA; Parham P
J Immunol; 2018 Feb; 200(3):1146-1158. PubMed ID: 29263215
[TBL] [Abstract][Full Text] [Related]
26. ZAP-70 in Signaling, Biology, and Disease.
Au-Yeung BB; Shah NH; Shen L; Weiss A
Annu Rev Immunol; 2018 Apr; 36():127-156. PubMed ID: 29237129
[TBL] [Abstract][Full Text] [Related]
27. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma.
Horwitz SM; Koch R; Porcu P; Oki Y; Moskowitz A; Perez M; Myskowski P; Officer A; Jaffe JD; Morrow SN; Allen K; Douglas M; Stern H; Sweeney J; Kelly P; Kelly V; Aster JC; Weaver D; Foss FM; Weinstock DM
Blood; 2018 Feb; 131(8):888-898. PubMed ID: 29233821
[TBL] [Abstract][Full Text] [Related]
28. A three-signal model of T-cell lymphoma pathogenesis.
Wilcox RA
Am J Hematol; 2016 Jan; 91(1):113-22. PubMed ID: 26408334
[TBL] [Abstract][Full Text] [Related]
29. B-cell receptor signaling in diffuse large B-cell lymphoma.
Young RM; Shaffer AL; Phelan JD; Staudt LM
Semin Hematol; 2015 Apr; 52(2):77-85. PubMed ID: 25805587
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling.
Dielschneider RF; Xiao W; Yoon JY; Noh E; Banerji V; Li H; Marshall AJ; Johnston JB; Gibson SB
Cell Death Dis; 2014 Oct; 5(10):e1439. PubMed ID: 25275600
[TBL] [Abstract][Full Text] [Related]
31. Premature terminal differentiation protects from deregulated lymphocyte activation by ITK-Syk.
Bach MP; Hug E; Werner M; Holch J; Sprissler C; Pechloff K; Zirlik K; Zeiser R; Dierks C; Ruland J; Jumaa H
J Immunol; 2014 Feb; 192(3):1024-33. PubMed ID: 24376268
[TBL] [Abstract][Full Text] [Related]
32. B-cell receptor signaling as a driver of lymphoma development and evolution.
Niemann CU; Wiestner A
Semin Cancer Biol; 2013 Dec; 23(6):410-21. PubMed ID: 24060900
[TBL] [Abstract][Full Text] [Related]
33. T-cell receptor signaling in peripheral T-cell lymphoma - a review of patterns of alterations in a central growth regulatory pathway.
Warner K; Weit N; Crispatzu G; Admirand J; Jones D; Herling M
Curr Hematol Malig Rep; 2013 Sep; 8(3):163-72. PubMed ID: 23892905
[TBL] [Abstract][Full Text] [Related]
34. Signaling of the ITK (interleukin 2-inducible T cell kinase)-SYK (spleen tyrosine kinase) fusion kinase is dependent on adapter SLP-76 and on the adapter function of the kinases SYK and ZAP70.
Hussain A; Mohammad DK; Gustafsson MO; Uslu M; Hamasy A; Nore BF; Mohamed AJ; Smith CI
J Biol Chem; 2013 Mar; 288(10):7338-50. PubMed ID: 23293025
[TBL] [Abstract][Full Text] [Related]
35. The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease.
Dierks C; Adrian F; Fisch P; Ma H; Maurer H; Herchenbach D; Forster CU; Sprissler C; Liu G; Rottmann S; Guo GR; Katja Z; Veelken H; Warmuth M
Cancer Res; 2010 Aug; 70(15):6193-204. PubMed ID: 20670954
[TBL] [Abstract][Full Text] [Related]
36. ZAP-70: an essential kinase in T-cell signaling.
Wang H; Kadlecek TA; Au-Yeung BB; Goodfellow HE; Hsu LY; Freedman TS; Weiss A
Cold Spring Harb Perspect Biol; 2010 May; 2(5):a002279. PubMed ID: 20452964
[TBL] [Abstract][Full Text] [Related]
37. The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma.
Pechloff K; Holch J; Ferch U; Schweneker M; Brunner K; Kremer M; Sparwasser T; Quintanilla-Martinez L; Zimber-Strobl U; Streubel B; Gewies A; Peschel C; Ruland J
J Exp Med; 2010 May; 207(5):1031-44. PubMed ID: 20439541
[TBL] [Abstract][Full Text] [Related]
38. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.
Ambrogio C; Martinengo C; Voena C; Tondat F; Riera L; di Celle PF; Inghirami G; Chiarle R
Cancer Res; 2009 Nov; 69(22):8611-9. PubMed ID: 19887607
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines.
Wilcox RA; Sun DX; Novak A; Dogan A; Ansell SM; Feldman AL
Leukemia; 2010 Jan; 24(1):229-32. PubMed ID: 19776763
[No Abstract] [Full Text] [Related]
40. The T-cell-receptor signaling network.
Huse M
J Cell Sci; 2009 May; 122(Pt 9):1269-73. PubMed ID: 19386893
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
